Opendata, web and dolomites

PhagoPROD SIGNED

GMP manufacturing & GLP diagnostic: Towards a personalised phage therapy against antimicrobial resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PhagoPROD project word cloud

Explore the words cloud of the PhagoPROD project. It provides you a very rough idea of what is the project "PhagoPROD" about.

first    status    relationships    2006    pathogenic    patients    benefits    hopeful    france    commercial    gmp    launch    glp    50    infections    prescribers    building    plague    pherecydes    compassionate    forecast    usa    lasting    customers    le    scaling    world    notably    phage    ansm    90    manufacture    deaths    selling    bacteria    validated    associations    designed    million    hospitals    portfolio    multicentric    attributable    500    laboratory    2017    reaching    patented    lien    french    setting    curent    human    resistant    final    administrate    2050    authorisation    pharma    answer    suffering    1st    transnational    frame    regard    bacteriophages    sme    clinical    successes    company    levels    optimising    created    therapeutic    antibiotic    phages    drug    centres    leader    therapy    phagespoirs    buyers    bacterial    pharmacists    diagnostics    hospital    ultimate    demonstrated    manufacturing    treatment    phagoprod    point    ones    almost   

Project "PhagoPROD" data sheet

The following table provides information about the project.

Coordinator
PHERECYDES PHARMA SA 

Organization address
address: NANTES BIOTECH 22 BOULEVARD BENONI GOULLIN
city: NANTES
postcode: 44200
website: www.pherecydes-pharma.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙764˙172 €
 EC max contribution 2˙446˙712 € (65%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHERECYDES PHARMA SA FR (NANTES) coordinator 2˙446˙712.00

Map

 Project objective

Phage therapy, that is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections, is a highly promising answer to the antibiotic resistant plague (500 000 deaths a year attributable to multi-drug resistant bacteria today, 10 million forecast by 2050). In this hopeful field, Pherecydes Pharma, a French SME created in 2006, is currently the world leader of phage therapy, with a a unique selling point and value proposal: (1) Patented technology; (2) Curent product portfolio covering over 50% of human infections and almost 90% of multi-drug resistant ones; (3) Ability to manufacture phages in GMP conditions; (4) 1st company to launch a transnational, well-designed, well-controlled, multicentric clinical study; (5) French authorisation (ANSM) in 2017 to administrate Pherecydes Pharma bacteriophages under a compassionate use status. Building on these successes, the PhagoPROD project aims at setting-up, optimising and scaling-up the GMP manufacturing and GLP diagnostics processes currently validated and demonstrated at laboratory scale. In that so, the ultimate objective is to achieve large-scale commercial exploitation of Pherecydes Pharma products first at the EU then at the USA levels (world reaching is planned in the long term). In the frame of this future commercial exploitation, targeted final users will be patients suffering from bacterial infections, notably antibiotic-resistant ones. Customers (i.e. buyers of Pherecydes Pharma products) will be clinical prescribers and hospital pharmacists. In this regard, Pherecydes already benefits from strong and long-lasting relationships with many hospitals and clinical centres in France and in Europe, as well as with several patients' associations (e.g. Le Lien or Phagespoirs).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHAGOPROD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHAGOPROD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Close (2019)

Redefining the customer journey of live event visitors

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More